Quest Diagnostics
Phrase of the vital scientific review aided medical-services company Quest Diagnostics negotiate a almost $200 million discount in its offer to acquire Celera Corp. However a single puzzle continues to be unsolved.
The deal talks were nonetheless under wraps. More than the subsequent month, Celera shares fell over 10% even though the biotechnology index was flat. In late November Quest created a bid of $7 a share, which was later on revised to $8.
Read more detail at 
